Organ On Chips MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy Organ ModelBy ApplicationBy End UserBy Technology
Full title & scope — all 5 axes with their segments
Organ On Chips Market Size, Share & Industry Analysis, By Product Type (Instruments & Devices, Consumables, Software & Services), By Organ Model (Liver-on-Chip, Lung-on-Chip, Kidney-on-Chip, Heart-on-Chip, Multi-Organ / Other Models), By Application (Drug Discovery & Development, Toxicology & Safety Testing, Disease Modeling, Personalized Medicine & Other Applications), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Government Research Institutes, Cosmetics & Other Industries), By Technology (Single-Organ-on-Chip Systems, Multi-Organ (Body-on-Chip) Systems), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By Product TypeInstruments & Devices · Consumables · Software & Services
- 02By Organ ModelLiver-on-Chip · Lung-on-Chip · Kidney-on-Chip
- 03By ApplicationDrug Discovery & Development · Toxicology & Safety Testing · Disease Modeling
- 04By End UserPharmaceutical & Biotechnology Companies · Contract Research Organizations · Academic & Government Research Institutes
- 05By TechnologySingle-Organ-on-Chip Systems · Multi-Organ
- 06By Region
Market Analysis & Outlook
Organ-on-chip systems are microfluidic devices that recreate the structure and function of a specific human tissue or organ on a small chip, used to observe how living cells respond to a drug, chemical or disease condition under controlled flow and mechanical conditions. Buyers are primarily pharmaceutical and biotechnology researchers evaluating drug candidates before animal or clinical testing, alongside contract research organizations, academic laboratories and, increasingly, cosmetics and chemical safety testing groups seeking an alternative to animal-based methods. The category spans standalone chip devices, the instruments that operate them, and the software used to capture and interpret the resulting data.
Growth of 23.57% a year carries the global organ on chips market from USD 105 million in 2025 to USD 718 million in 2034. The full series behind that rate covers USD 30 million in 2020, USD 81 million in 2024, USD 132 million in 2026 and USD 329 million in 2030, with 2025 as the base year.
Composition changes more than the total does. Software & Services, at 26.34%, outgrows Instruments & Devices at 20.91%, and its share moves from 18% to 22%. Consumables (Chips & Reagents) stays the largest line throughout, at USD 50.4 million in 2025 and USD 359 million in 2034. Share moves toward Consumables (Chips & Reagents) and Software & Services and away from Instruments & Devices, though no line shrinks in revenue terms.
The organ model split puts Liver-on-Chip first, at USD 31.5 million and 30% of revenue in 2025, rising to USD 193.86 million and 27% in 2034. Multi-Organ / Other Models grows faster at 26.36% against 22.38%, moving from 20% of revenue to 24% by 2034. It cuts the same total as the product type axis from a different commercial angle, so revenue does not add across the two.
The regional order runs from North America at 42% of 2025 revenue down to Middle East and Africa at 3%. North America is worth USD 44.1 million in 2025 and USD 272.84 million in 2034; Europe, second at 30%, moves from USD 31.5 million to USD 193.86 million. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, three product type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD MillionRevenue in USD Million. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global organ on chips market moves from USD 30 million in 2020 to USD 105 million in 2025 and USD 718 million by 2034, the forecast period compounding at 23.57% a year.
- Consumables (Chips & Reagents) is the largest product type line at USD 50.4 million in 2025, a 48% share, reaching USD 359 million and 50% of revenue by 2034.
- At 26.34%, Software & Services grows faster than any other product type line, moving from USD 18.9 million and 18% of revenue in 2025 to USD 157.96 million and 22% in 2034.
- The bull case puts 2034 revenue at USD 811 million and the bear case at USD 617 million, either side of the USD 718 million base case, each with its own stated assumption in the full report.
- North America holds 42% of global revenue in 2025 at USD 44.1 million, the largest of the five regions tracked, and reaches USD 272.84 million by 2034.
- The United States accounts for 90% of North America in the base year, worth USD 39.69 million in 2025 and reaching USD 245.56 million by 2034, the worked country example carried through that region's chapters.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By Product Type
Base year 2025Consumables (Chips & Reagents) leads with 48.0% of product type segment revenue.
Share of product type segment revenue, most recent base year.
The global organ on chips market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 23.57% rate carrying the total.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
The product type mix tilts toward Software & Services. Software & Services grows at 26.34% across 2026-2034 against 20.91% for Instruments & Devices, the widest spread on the product type axis. Shares follow: 18% to 22% for Software & Services, 34% to 28% for Instruments & Devices. Revenue rises on both sides; USD 18.9 million to USD 157.96 million and USD 35.7 million to USD 201.04 million respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
The regional balance moves. Asia Pacific moves from 21% of revenue in 2025 to 27% in 2034, worth USD 22.05 million rising to USD 193.86 million; Latin America moves from 4% of revenue in 2025 to 5% in 2034, worth USD 4.2 million rising to USD 35.9 million. The remaining regions grow in absolute terms while giving up share: North America at 42% moving to 38%, Europe at 30% moving to 27%, Middle East and Africa at 3% moving to 3%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
Fifteen years without a discontinuity. Fifteen years of revenue run USD 30 million in 2020, USD 81 million in 2024, USD 105 million in 2025, USD 132 million in 2026, USD 329 million in 2030 and USD 718 million in 2034. Against 28.48% through the historical period, the 23.57% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the product type and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Software & Services adds the most incremental growth
Market Drivers
3- 01Software & Services adds the most incremental growth
26.34% growth in Software & Services, against 23.57% for the market as a whole, moves it from USD 18.9 million and 18% of revenue in 2025 to USD 157.96 million and 22% in 2034. Set against 20.91% at the other end of the axis, this is the line that decides whether the market's 23.57% holds. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Regional weight, not regional count
42% of 2025 revenue (USD 44.1 million) is generated in North America, reaching USD 272.84 million by 2034 at an unchanged 38%. Behind it, Europe holds 30%; USD 31.5 million rising to USD 193.86 million. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03The base has grown every year since 2020
Revenue rose through USD 30 million in 2020, USD 81 million in 2024 and USD 105 million in 2025, a compound 28.48% across the historical period. The forecast period then runs at 23.57%, ending 2034 at USD 718 million. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 23.57% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Regulatory shift away from mandatory animal testing (FDA Modernization Act 2.0 and comparable reforms) | High | +190 | High | High | Medium |
| 2 | Pharmaceutical R&D adoption of organ-chip platforms to reduce late-stage drug attrition | High | +165 | High | High | High |
| 3 | Expansion of multi-organ and body-on-chip systems enabling cross-tissue disease modeling | Medium-High | +110 | Medium | High | High |
| 4 | Cosmetics and consumer-product industry adoption driven by regional animal-testing bans | Medium | +75 | Medium | Medium | High |
| 5 | Rising investment in personalized and patient-derived tissue chip research | Medium | +55 | Low | Medium | Medium |
| 6 | Other unattributed demand factors | Low | +93 | Medium | Medium | Medium |
| Total | +688 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High cost and technical complexity of chip fabrication and validation limiting smaller-lab adoption | Medium | −45 | High | Medium | Low |
| 2 | Limited standardization and regulatory acceptance pathways slowing large-scale replacement of animal models | Medium | −30 | Medium | Medium | Low |
| Total | −75 | |||||
Drivers contribute 688 Million and restraints remove 75 Million, a net 613 Million, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 23.57% into its parts and three show up: an already-large base compounding, the product type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 617 million by 2034, against USD 718 million in the base case
Market Restraints
2- 01Downside case: USD 617 million by 2034, against USD 718 million in the base case
Where the forecast could miss: regulatory acceptance of chip-based data advances more slowly than current guidance implies, keeping animal protocols as the default for a larger share of drug-safety studies through the forecast period. That path reaches USD 617 million by 2034 instead of USD 718 million, off an unchanged USD 105 million in 2025.
- 02Instruments & Devices holds the blended rate down
Instruments & Devices carries 34% of 2025 revenue at USD 35.7 million but compounds at 20.91% against 23.57% for the market, taking its share to 28% by 2034 even as revenue rises to USD 201.04 million. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 811 million by 2034
Market Opportunities
2- 01Upside case: USD 811 million by 2034
Regulatory agencies fast-track acceptance of organ-chip data across more indications, moving pharmaceutical sponsors away from animal protocols faster than current guidance implies. On that assumption the market reaches USD 811 million by 2034 against USD 718 million in the base case, from the same USD 105 million in 2025.
- 02The opening is on the product type axis, not the regional one
Share on the product type axis moves toward Software & Services, from 18% in 2025 to 22% in 2034, on 26.34% growth against the market's 23.57% and revenue rising from USD 18.9 million to USD 157.96 million. Taking position there does not require displacing whoever holds Consumables (Chips & Reagents), which is the harder and more expensive fight.
Market Challenges
Concentration on the product type axis
Market Challenges
2- 01Concentration on the product type axis
Consumables (Chips & Reagents) is 48% of 2025 revenue at USD 50.4 million and still 50% at USD 359 million in 2034. A market leaning this heavily on one product type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02Single-country exposure in North America
Of North America's USD 44.1 million in 2025, USD 39.69 million (90%) comes from the United States alone, rising to USD 245.56 million by 2034. Read as a region it looks diversified; read by weight it is not, and the regional forecast inherits whatever happens in that one market.
Segmentation Analysis
5 axesThe market is divided by product type and by organ model, application, end user and technology; five axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
All three product type lines expand in revenue terms over the forecast period. Share is the dividing line; two take it, the other cedes it.
By Product Type · 3 segments
Scale in Consumables (Chips & Reagents) and Growth in Software & Services Define the Product type Axis
- Largest Consumables (Chips & Reagents) · 48%
- Fastest Software & Services · 26.3%
- Moves most Instruments & Devices · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Instruments & Devices | $35.70M | 34% | $201M | 28%-6 | 20.9% |
| Consumables (Chips & Reagents) | $50.40M | 48% | $359M | 50%+2 | 24.1% |
| Software & Services | $18.90M | 18% | $158M | 22%+4 | 26.3% |
Consumables lead because each experiment or study consumes a fresh chip, creating a recurring revenue stream tied to protocol volume rather than one-time instrument sales. Software and services grow fastest as labs need data analysis, image processing and modeling support to interpret multi-parameter readouts from increasingly complex chip designs, a need that grows with chip sophistication rather than with unit count alone. The order does not change: Consumables (Chips & Reagents) is still largest in 2034, and what moves is how much it holds. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Organ Model · 5 segments
Liver-on-Chip Led by Organ model in 2025, with Multi-Organ / Other Models Growing Fastest
- Largest Liver-on-Chip · 30%
- Fastest Multi-Organ / Other Models · 26.4%
- Moves most Multi-Organ / Other Models · +4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Liver-on-Chip | $31.50M | 30% | $194M | 27%-3 | 22.4% |
| Lung-on-Chip | $21M | 20% | $136M | 19%-1 | 23.1% |
| Kidney-on-Chip | $15.75M | 15% | $108M | 15% | 23.8% |
| Heart-on-Chip | $15.75M | 15% | $108M | 15% | 23.8% |
| Multi-Organ / Other Models | $21M | 20% | $172M | 24%+4 | 26.4% |
Liver models lead because hepatotoxicity is the most common reason a drug candidate fails, making liver-on-chip the first validation step most drug developers adopt. Multi-organ and other integrated models grow fastest as researchers move beyond single-organ toxicity screening toward systems that capture how drugs behave once absorbed, metabolized and cleared across connected tissues, a use case single-organ chips cannot address. By 2034 Liver-on-Chip is still ahead, making this a shift in weight, not a change of leader.
By Application · 4 segments
Personalized Medicine & Other Applications Outpaces the Axis While Drug Discovery & Development Holds the Largest Share
- Largest Drug Discovery & Development · 45%
- Fastest Personalized Medicine & Other Applications · 28.5%
- Moves most Toxicology & Safety Testing · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Drug Discovery & Development | $47.25M | 45% | $309M | 43%-2 | 23.2% |
| Toxicology & Safety Testing | $31.50M | 30% | $187M | 26%-4 | 21.9% |
| Disease Modeling | $15.75M | 15% | $122M | 17%+2 | 25.6% |
| Personalized Medicine & Other Applications | $10.50M | 10% | $101M | 14%+4 | 28.5% |
Drug discovery and development leads because pharmaceutical sponsors are the primary buyers funding chip adoption to de-risk candidates before costly animal and clinical stages. Personalized medicine and other niche uses grow fastest as academic and specialty labs begin applying patient-derived tissue chips to individualized treatment response questions, a newer but rapidly expanding use case within the same buyer base. By 2034 Drug Discovery & Development is still ahead, making this a shift in weight, not a change of leader.
By End User · 4 segments
Pharmaceutical & Biotechnology Companies Led by End user in 2025, with Cosmetics & Other Industries Growing Fastest
- Largest Pharmaceutical & Biotechnology Companies · 52%
- Fastest Cosmetics & Other Industries · 30.4%
- Moves most Cosmetics & Other Industries · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical & Biotechnology Companies | $54.60M | 52% | $359M | 50%-2 | 23.3% |
| Contract Research Organizations | $26.25M | 25% | $187M | 26%+1 | 24.4% |
| Academic & Government Research Institutes | $18.90M | 18% | $115M | 16%-2 | 22.2% |
| Cosmetics & Other Industries | $5.25M | 5% | $57.44M | 8%+3 | 30.4% |
Pharmaceutical and biotechnology companies lead because they carry both the R&D budgets and the regulatory incentive to reduce reliance on animal models before submissions. Cosmetics and other industries grow fastest as bans on animal testing for cosmetic ingredients in multiple jurisdictions push formulators toward validated alternative testing platforms for the first time, a shift only beginning from a small base. Pharmaceutical & Biotechnology Companies remains the largest line through 2034, so the axis changes in proportion, not in order.
By Technology · 2 segments
Multi-Organ (Body-on-Chip) Systems Outpaces the Axis While Single-Organ-on-Chip Systems Holds the Largest Share
- Largest Single-Organ-on-Chip Systems · 68%
- Fastest Multi-Organ (Body-on-Chip) Systems · 27.6%
- Moves most Single-Organ-on-Chip Systems · -10 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single-Organ-on-Chip Systems | $71.40M | 68% | $416M | 58%-10 | 21.6% |
| Multi-Organ (Body-on-Chip) Systems | $33.60M | 32% | $302M | 42%+10 | 27.6% |
Single-organ systems lead because they remain simpler to validate, manufacture and integrate into an existing lab workflow, making them the default entry point for a new adopter. Multi-organ and body-on-chip systems grow fastest as sponsors seek to model interactions between tissues, such as gut-liver or liver-kidney crosstalk, that a single-organ chip is not built to capture. By 2034 Single-Organ-on-Chip Systems is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 4 points of share move elsewhere by 2034, while revenue still grows 6.2×.
- Rank 1 of 5
- 2025 share 42%
- By 2034 38%
- Revenue $44.10M → $273M
USD 44.1 million of 2025 revenue is generated in North America, 42% of the global organ on chips market and reaches USD 272.84 million by 2034. Among the five regions it ranks first by revenue in both years.
Its share moves to 38% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Segment composition follows the global pattern: Consumables (Chips & Reagents) largest at 48% of 2025 revenue, Software & Services fastest at 26.34%. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 90% of it, growing 6.2×.
- In region 1 of 2
- Of region 90%
- Of global 37.8%
- Revenue $39.69M → $246M
The largest single market in North America is the United States, at USD 39.69 million in 2025 and USD 245.56 million in 2034. At 90% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 44.1 million in 2025 and USD 272.84 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Composition here matches the global split: the largest line is Consumables (Chips & Reagents) at 48% of 2025 revenue, easing to 50% by 2034, and the fastest is Software & Services at 26.34%, from 18% to 22%. Because the country carries 90% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product type for the United States is reported separately in the full report.
In the United States, organ-on-chip systems function mainly as preclinical research tools used ahead of clinical testing, so most fall outside the FDA's medical device approval pathway unless a supplier makes a direct diagnostic or therapeutic claim for the device itself. The Food and Drug Administration has instead focused on how data generated from these microphysiological systems can be qualified and accepted to support investigational new drug submissions, shifting scrutiny toward the drug development use of the platform. Suppliers marketing chips for laboratory use are expected to meet general laboratory equipment safety practices, and any system incorporating human-derived cells must also observe biosafety and tissue-handling requirements set by public health authorities. Labelling should accurately describe intended research use to avoid triggering device classification.
The suppliers tracked in this study (Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis) compete in the United States across the product type lines above. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.
Canada
2nd-largest in North America, growing 6.2×.
- In region 2 of 2
- Of region 10%
- Of global 4.2%
- Revenue $4.41M → $27.28M
4.2% of global revenue is generated in Canada; USD 4.41 million in 2025, reaching USD 27.28 million in 2034, and 10% of North America.
Europe Market Analysis
The 2nd-largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 6.2×.
- Rank 2 of 5
- 2025 share 30%
- By 2034 27%
- Revenue $31.50M → $194M
Europe holds 30% of the global organ on chips market in 2025, worth USD 31.5 million and reaches USD 193.86 million by 2034. It is a leading region on this axis, second by revenue throughout the period.
By 2034 the share stands at 27%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Segment composition follows the global pattern: Consumables (Chips & Reagents) largest at 48% of 2025 revenue, Software & Services fastest at 26.34%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 6.2×.
- In region 1 of 3
- Of region 38%
- Of global 11.4%
- Revenue $11.97M → $73.67M
USD 11.97 million of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 73.67 million by 2034. It accounts for 38% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 31.5 million in 2025 and USD 193.86 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Germany follows the product type mix reported at global level: Consumables (Chips & Reagents) is the largest line at 48% of 2025 revenue, moving to 50% by 2034, while Software & Services grows fastest at 26.34% and takes its share from 18% to 22%. Because the country carries 38% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Germany carries its own product type breakdown in the full report.
In Germany, organ-on-chip platforms sold for pharmaceutical and academic research are treated as laboratory instruments rather than medical devices, since they are not intended for direct diagnosis or treatment of a patient, and so they sit outside the scope enforced by the Federal Institute for Drugs and Medical Devices. Where a system incorporates human tissue or cell lines, suppliers must instead satisfy the country's biological safety and genetic engineering rules covering handling of biological material in a laboratory setting, alongside general product safety and machinery conformity marking that applies to laboratory apparatus sold within the European Union. Should a manufacturer later position a chip for diagnostic use, it would move under the EU's in vitro diagnostic medical device framework, bringing conformity assessment and post market surveillance obligations into force.
Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis are the suppliers covered in Germany. Volume sits in Consumables (Chips & Reagents) at 48% of 2025 revenue; movement sits in Software & Services at 26.34% growth. Weighting toward Europe means competing for 30% of 2025 global revenue, a base of USD 31.5 million moving to USD 193.86 million across the forecast period.
Switzerland
2nd-largest in Europe, growing 6.2×.
- In region 2 of 3
- Of region 32%
- Of global 9.6%
- Revenue $10.08M → $62.04M
Within Europe, Switzerland accounts for 32% of regional revenue and 9.6% of the global total, worth USD 10.08 million in 2025 and USD 62.04 million by 2034.
United Kingdom
3rd-largest in Europe, growing 6.2×.
- In region 3 of 3
- Of region 20%
- Of global 6%
- Revenue $6.30M → $38.77M
Within Europe, the United Kingdom accounts for 20% of regional revenue and 6% of the global total, worth USD 6.3 million in 2025 and USD 38.77 million by 2034.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 6 points of share by 2034, while revenue still grows 8.8×.
- Rank 3 of 5
- 2025 share 21%
- By 2034 27%
- Revenue $22.05M → $194M
Asia Pacific holds 21% of the global organ on chips market in 2025, worth USD 22.05 million and reaches USD 193.86 million by 2034. Among the five regions it ranks third by revenue in both years.
Its share rises to 27% over the forecast period, because it outgrows the market's 23.57%; the revenue added here is disproportionate to where the region started.
The product type mix reported at global level applies here, with Consumables (Chips & Reagents) the largest line at 48% of 2025 revenue and Software & Services the fastest-growing at 26.34%. The full report breaks Asia Pacific out along every axis and by country.
Japan
The largest market in Asia Pacific, growing 8.8×.
- In region 1 of 3
- Of region 35%
- Of global 7.3%
- Revenue $7.72M → $67.85M
Japan is the largest market within Asia Pacific, generating USD 7.72 million in 2025 and projected to reach USD 67.85 million by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 22.05 million in 2025 and USD 193.86 million in 2034, it is the country the full report breaks out in detail.
The product type pattern in Japan is the global one: 48% of 2025 revenue in Consumables (Chips & Reagents), 50% by 2034, against 26.34% growth in Software & Services taking it from 18% to 22%. Because the country carries 35% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product type for Japan is reported separately in the full report.
In Japan, organ-on-chip systems intended for laboratory and drug discovery use are generally treated as research equipment outside the scope of the Pharmaceuticals and Medical Devices Act, since that law targets devices used for diagnosis or treatment of a patient and not tools applied earlier in the development pipeline. The Pharmaceuticals and Medical Devices Agency has shown willingness to accept data produced on qualified microphysiological systems as supporting evidence within a drug application, placing its oversight on scientific validation of the platform's results instead of on licensing the hardware itself. A chip incorporating living human or animal cells must still meet the country's biosafety and laboratory handling standards for biological material, and any claim of diagnostic function would require the supplier to pursue device approval under the same Act.
Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis are the suppliers covered in Japan. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. A supplier weighted toward Asia Pacific is competing over a base of USD 22.05 million in 2025 reaching USD 193.86 million by 2034, 21% of global revenue at the start of that period.
China
2nd-largest in Asia Pacific, growing 8.8×.
- In region 2 of 3
- Of region 30%
- Of global 6.3%
- Revenue $6.62M → $58.16M
Within Asia Pacific, China accounts for 30% of regional revenue and 6.3% of the global total, worth USD 6.62 million in 2025 and USD 58.16 million by 2034.
South Korea
3rd-largest in Asia Pacific, growing 8.8×.
- In region 3 of 3
- Of region 20%
- Of global 4.2%
- Revenue $4.41M → $38.77M
Within Asia Pacific, South Korea accounts for 20% of regional revenue and 4.2% of the global total, worth USD 4.41 million in 2025 and USD 38.77 million by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 8.5×.
- Rank 4 of 5
- 2025 share 4%
- By 2034 5%
- Revenue $4.20M → $35.90M
4% of the global organ on chips market sits in Latin America in 2025, worth USD 4.2 million and reaches USD 35.9 million by 2034. Among the five regions it ranks fourth by revenue in both years.
5% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 23.57%; the revenue added here is disproportionate to where the region started.
Within the region the product type split tracks the global one; 48% of 2025 revenue in Consumables (Chips & Reagents), fastest growth of 26.34% in Software & Services. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
Sets the pace for Latin America at 60% of it, growing 8.5×.
- In region 1 of 2
- Of region 60%
- Of global 2.4%
- Revenue $2.52M → $21.54M
USD 2.52 million of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 21.54 million by 2034. 60% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 4.2 million and USD 35.9 million for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Consumables (Chips & Reagents) at 48% of 2025 revenue, easing to 50% by 2034, and the fastest is Software & Services at 26.34%, from 18% to 22%. Its 60% weight in Latin America means those movements carry straight into the regional totals. The full report reports Brazil by product type separately.
In Brazil, organ-on-chip devices marketed for research and drug screening purposes are generally treated as laboratory instruments and fall outside the medical device registration requirements enforced by the National Health Surveillance Agency, since that authority's remit centers on devices intended for direct diagnosis or treatment of a patient. A supplier working with human or animal derived cell lines must instead observe the biosafety approval process overseen by the National Technical Biosafety Commission, covering handling and containment of biological material used inside the chip. Should a manufacturer seek to market a chip with a diagnostic claim, the device would need to be classified and registered with the health surveillance agency before sale, bringing labelling and quality system obligations that do not otherwise apply to a research-only instrument.
Competition in Brazil runs between the suppliers this study tracks: Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis. The commercially relevant division is 48% of 2025 revenue in Consumables (Chips & Reagents), where the volume is, against 26.34% growth in Software & Services, where share moves. A supplier weighted toward Latin America is competing over a base of USD 4.2 million in 2025 reaching USD 35.9 million by 2034, 4% of global revenue at the start of that period.
Mexico
2nd-largest in Latin America, growing 8.5×.
- In region 2 of 2
- Of region 30%
- Of global 1.2%
- Revenue $1.26M → $10.77M
Mexico is sized at USD 1.26 million in 2025, rising to USD 10.77 million by 2034; 1.2% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 6.8×.
- Rank 5 of 5
- 2025 share 3%
- By 2034 3%
- Revenue $3.15M → $21.54M
3% of the global organ on chips market sits in Middle East and Africa in 2025, worth USD 3.15 million and reaches USD 21.54 million by 2034. Among the five regions it ranks fifth by revenue in both years.
3% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
Within the region the product type split tracks the global one; 48% of 2025 revenue in Consumables (Chips & Reagents), fastest growth of 26.34% in Software & Services. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
Israel
The largest market in Middle East and Africa, growing 6.8×.
- In region 1 of 2
- Of region 55%
- Of global 1.6%
- Revenue $1.73M → $11.85M
The largest single market in Middle East and Africa is Israel, at USD 1.73 million in 2025 and USD 11.85 million in 2034. Its 55% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 3.15 million to USD 21.54 million over the same period, and this is the market carrying the country-level detail in the full report.
Israel buys along the same lines as the market globally; Consumables (Chips & Reagents) first at 48% of 2025 revenue and 50% in 2034, Software & Services fastest at 26.34% on a share moving from 18% to 22%. With 55% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product type revenue for Israel appears on its own in the full report.
In Israel, organ-on-chip platforms intended for laboratory and preclinical research use sit outside the medical device licensing process administered by the Ministry of Health's Medical Device division, because that process is reserved for devices intended for direct patient diagnosis or treatment. A laboratory working with human or animal cell material inside these systems must still meet the ministry's biosafety and laboratory practice requirements governing handling of biological material, and any system supplied for use in a certified laboratory is expected to conform to general laboratory equipment and electrical safety standards. Where a developer later seeks to market a chip with a diagnostic intended use, that device would then require full registration and classification under the country's medical device law before it could be sold or used clinically.
Competition in Israel runs between the suppliers this study tracks: Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis. Two different problems sit on the same axis: holding Consumables (Chips & Reagents) at 48% of 2025 revenue, and taking Software & Services while it grows at 26.34%. A supplier weighted toward Middle East and Africa is competing over a base of USD 3.15 million in 2025 reaching USD 21.54 million by 2034, 3% of global revenue at the start of that period.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 6.8×.
- In region 2 of 2
- Of region 25%
- Of global 0.8%
- Revenue $0.79M → $5.39M
0.75% of global revenue is generated in the United Arab Emirates; USD 0.79 million in 2025, reaching USD 5.39 million in 2034, and 25% of Middle East and Africa.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product Type, Organ Model, Application, End User, Technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Position on the Product type Axis Decides Competitive Standing
Suppliers in scope: Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim and Nortis.
Competition follows the product type split, not the regional one. The largest block of revenue is Consumables (Chips & Reagents): USD 50.4 million in 2025 at 48% of the total, 50% in 2034. Incumbency there is expensive to challenge. Movement is concentrated in Software & Services; 26.34% growth, against 20.91% at the other end of the axis in Instruments & Devices. The two rarely sit with the same supplier, and that is the reason a USD 105 million market is not already consolidated.
Suppliers differentiate mainly on validation depth: whether a chip's readouts have been checked against pharmacology or toxicology outcomes a pharmaceutical buyer already trusts. Manufacturing precision in microfluidic channel design and reproducibility across chip batches decides who wins repeat orders, since inconsistent flow characteristics undermine an entire study. The largest suppliers hold broad multi-organ platforms and established pharmaceutical partnerships built over successive validation cycles. Smaller and regional suppliers compete on single-organ specialization, custom chip fabrication for a specific tissue type, and closer academic collaboration, where a tailored design matters more than platform breadth.
Geographic reach is the other axis of competition. North America alone accounts for 42% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; Europe adds a further 30%.
Profiles, financials, shares and development histories for each company sit in the full report; this summary carries the structure only.
List of Key Organ On Chips Market Companies Profiled
10 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Mimetas (Netherlands)
- Emulate (US)
- InSphero (Switzerland)
- CN Bio Innovations(United Kingdom)
- BioIVT(United States)
- Kirkstall(United Kingdom)
- Visikol(United States)
- SynVivo(United States)
- AxoSim(United States)
- Nortis(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Product Type, Organ Model, Application, End User, Technology), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 10 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Organ On Chips Market Size & Projections, 2020–2034, Revenue (USD Million)
Chapter 16.Global Organ On Chips Market Overview, By Product Type, 2020–2034, Revenue (USD Million)
Chapter 17.Global Organ On Chips Market Overview, By Organ Model, 2020–2034, Revenue (USD Million)
Chapter 18.Global Organ On Chips Market Overview, By Application, 2020–2034, Revenue (USD Million)
Chapter 19.Global Organ On Chips Market Overview, By End User, 2020–2034, Revenue (USD Million)
Chapter 20.Global Organ On Chips Market Overview, By Technology, 2020–2034, Revenue (USD Million)
Chapter 21.Global Organ On Chips Market Size — Segment Comparison
Chapter 22.Global Organ On Chips Geography Overview, 2020–2034, Revenue (USD Million)
Chapter 23.North America Organ On Chips Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 24.Europe Organ On Chips Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 25.Asia Pacific Organ On Chips Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 26.Latin America Organ On Chips Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 27.Middle East and Africa Organ On Chips Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Product Type
3- 01Instruments & Devices
- 02Consumables (Chips & Reagents)
- 03Software & Services
By Organ Model
5- 01Liver-on-Chip
- 02Lung-on-Chip
- 03Kidney-on-Chip
- 04Heart-on-Chip
- 05Multi-Organ / Other Models
By Application
4- 01Drug Discovery & Development
- 02Toxicology & Safety Testing
- 03Disease Modeling
- 04Personalized Medicine & Other Applications
By End User
4- 01Pharmaceutical & Biotechnology Companies
- 02Contract Research Organizations
- 03Academic & Government Research Institutes
- 04Cosmetics & Other Industries
By Technology
2- 01Single-Organ-on-Chip Systems
- 02Multi-Organ (Body-on-Chip) Systems
Segment categories shown for scope reference. See the Summary tab for revenue share by Product Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
Sizing starts from the unit level: the number of chip devices and consumable cartridges shipped for drug-discovery, toxicology and academic protocols, multiplied by the realized price per chip or per study package charged by device suppliers and service providers. Instrument placements are counted separately from the recurring consumable draw they generate, since one instrument sale seeds a multi-year cartridge order stream. This bottom-up volume-times-price build is then checked against revenue disclosed by organ-chip suppliers and against contract-research pricing quoted for chip-based toxicology studies. Where the two diverge, the correction is made to the underlying unit-volume or price assumption feeding the bottom-up build, not by averaging in a separate top-down estimate.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary outreach targets the roles that actually decide chip adoption: procurement and R&D leads at pharmaceutical and biotechnology companies evaluating a platform switch, laboratory heads at contract research organizations pricing chip-based study packages, and regulatory affairs staff tracking how alternative-methods guidance is applied inside their own organization. Channel contacts at instrument distributors and chip manufacturers' commercial teams are also sampled to understand list pricing and typical discount ranges. Sampling weights toward North America and Western Europe, where organ-chip adoption is most advanced, with a smaller but deliberate sample in Japan and South Korea to capture faster-growing academic and regulatory interest.
Desk research draws on regulatory filings and clearance listings relevant to alternative test methods, including FDA guidance issued under the FDA Modernization Act 2.0 and correspondence published by the OECD's Test Guidelines Programme on microphysiological systems. Trade classification data under the relevant customs codes for laboratory and diagnostic instruments is used to estimate cross-border instrument shipments. Company-level inputs come from annual reports and investor materials of the larger organ-chip suppliers, supplemented by university and NIH-funded grant records disclosing organ-chip procurement for specific research programs, and by proceedings from the biannual World Congress on Alternatives and Animal Use in the Life Sciences.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the pace at which pharmaceutical sponsors are expected to substitute chip-based studies for a share of their existing animal-testing protocols, tied to phased FDA and EMA guidance timelines. Per-chip pricing is assumed to decline gradually as manufacturing scales, partly offset by larger average order sizes as multi-organ systems replace single-organ chips. The forecast normalizes for the small base that early adoption years represent, so a large percentage swing early in the period does not extrapolate into an unrealistic absolute figure later on. For the forecast to hold, regulatory acceptance of chip-based data must keep advancing rather than stalling at pilot-program status.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against the recorded revenue growth of publicly tracked organ-chip suppliers over the last three to four years, checking that the implied historical trajectory in this estimate does not diverge sharply from what those companies have already reported. Segment-level shifts, such as the move toward multi-organ systems and away from single-organ chips, were reviewed against recent academic publication trends and conference program content as an independent check on direction, not magnitude. Sensitivities were tested around the pace of regulatory acceptance and around chip pricing decline, since those two assumptions move the forecast total the most if either runs faster or slower than assumed.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Estimates for pharmaceutical end-use and for the liver and lung organ models are the firmest, since these rest on the most established adoption pattern and the clearest supplier disclosures. Figures for cosmetics-industry adoption, personalized-medicine applications and multi-organ systems are softer, since reporting from smaller specialty labs and newer platform categories is thinner and adoption is still forming. A structural risk to this estimate is a slower-than-assumed pace of regulatory acceptance for chip-based data in place of animal studies, which would compress the forecast without changing the historical base.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Organ On Chips Market projected to reach?
USD 718 Million by 2034, CAGR 23.57%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Consumables (Chips & Reagents) is the largest line by Product Type, at 48% of revenue in 2025.
06Who are the key companies profiled?
Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), CN Bio Innovations, BioIVT, Kirkstall, Visikol, SynVivo, AxoSim, Nortis. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.